GlassScriptPhysician profile
Ahmet Can
NPI 1518214626
$4,400.07
in general payments reported to CMS, 2019-2025
34 companies · $1,805 in 2025
The $1,805 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $41.60 · 2021: $99.39 · 2022: $62.77 · 2023: $764 · 2024: $924 · 2025: $1,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,387 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,387.01 |
| Education | $107.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $542.65 | 2021-2025 | Minimed 780g, Minimed 770g |
| Lilly USA, LLC | $519.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $471.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $435.77 | 2019-2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $368.79 | 2023-2025 | Unithroid |
| Insulet Corporation | $279.21 | 2023-2025 | Omnipod, Omnipod |
| Janssen Pharmaceuticals, INC | $161.34 | 2019 | |
| Ibsa Pharma INC. | $151.44 | 2023-2025 | Tirosint, Licart, Flector |
| Amgen INC. | $151.07 | 2019-2025 | Tepezza |
| Mannkind Corporation | $134.86 | 2025 | |
| Sanofi-Aventis U.S. LLC | $109.84 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $103.48 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $87.02 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.09 | 2023-2025 | |
| Pfizer INC. | $75.54 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $69.78 | 2023-2025 | Korlym |
| Medtronic Minimed, INC. | $65.99 | 2019-2020 | |
| Dexcom, INC. | $51.95 | 2022-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $51.84 | 2023-2025 | Synthroid |
| Valeritas, INC. | $49.66 | 2019 | |
| Xeris Pharmaceuticals, INC. | $48.42 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Alexion Pharmaceuticals, INC. | $45.52 | 2019 | |
| Ascensia Diabetes Care US INC. | $43.73 | 2024-2025 | |
| Radius Health, INC. | $41.58 | 2025 | |
| Astellas Pharma US INC | $36.28 | 2024-2025 | Veozah |
| Chiesi USA, INC. | $35.82 | 2025 | Mycapssa |
| Amryt Pharma Holdings LTD | $30.43 | 2023 | Myalept |
| Cequr Corporation | $29.54 | 2024-2025 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $28.96 | 2019 | |
| Acella Pharmaceuticals, LLC | $22.00 | 2023 | NP Thyroid 60 |
| Beta Bionics, INC. | $19.78 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Glaxosmithkline, LLC. | $19.40 | 2025 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.82 | 2019 | |
| Ascendis Pharma Endocrinology INC | $14.30 | 2025 | Yorvipath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmet Can listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.